We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. The Administrator of personal data is STOCKTRADEIQ sp. z o.o., with its registered office in Poznan (61-625), at the following address: Czarna Rola 30 Street. Cookies policy here. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

  • Cookie
    cookieyes-consent
  • Duration
    1 year
  • Description
    CookieYes sets this cookie to remember users' consent preferences so that their preferences are respected on their subsequent visits to this site. It does not collect or store any personal information of the site visitors.
  • Cookie
    x-ms-cpim-csrf
  • Duration
    session
  • Description

    Inter-site request forgery token used to protect crSF. For more information, read the section Token falsification of requests between sites.

  • Cookie
    x-ms-cpim-sso:stocktradeiqauth.onmicrosoft.com_0
  • Duration
    session
  • Description

    Used to support single sign-on sessions. This cookie is set as persistent when the Keep me logged in option is enabled.

  • Cookie
    server-telemetry-{id}
  • Duration
    persistent
  • Description

    A value used by Microsoft for authorisation and authentication.

  • Cookie
    google_auto_fc_cmp_setting
  • Duration
    persistent
  • Description


    Stores the state of the User cookie for the current domain.

     

  • Cookie
    {id}-https://stocktradeiqauth.onmicrosoft.com/{id}
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    msal{id}.active-account
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com-refreshtoken
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com-idtoken
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    Microsoft Clarity
  • Duration
    1 year
  • Description

    Microsoft Clarity

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

  • Cookie
    isLightMode
  • Duration
    1 year
  • Description

    Defines the UI theme

  • Cookie
    userCultureData
  • Duration
    persistent
  • Description

     Stores information about the user's machine culture.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

  • Cookie
    _ga
  • Duration
    1 year 1 month 4 days
  • Description
    The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
  • Cookie
    _ga_*
  • Duration
    1 year 1 month 4 days
  • Description
    Google Analytics sets this cookie to store and count page views.
  • Cookie
    hotjar
  • Duration
    1 year 1 month 4 days
  • Description

    Analyzing users' behaviour in the website

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

  • Cookie
    __gpi
  • Duration
    1 year 24 days
  • Description
    Google Ads Service uses this cookie to collect information about from multiple websites for retargeting ads.
  • Cookie
    __gads
  • Duration
    1 year 24 days
  • Description

    The file, set by Google, is stored in the DoubleClick domain and tracks the number of times users view an ad, measures the success of the campaign and calculates its revenue. This cookie can only be read from the domain where it is set and does not track any data when browsing other sites.

  • Cookie
    goog:cached:topics
  • Duration
    persistent
  • Description

    It is used to record which adverts have been displayed to the User.

  • Cookie
    IDE
  • Duration
    year
  • Description

    Used by Google DoubleClick to record and report on the Website User's actions after viewing or clicking on an advertiser's ads in order to measure the effectiveness of the ad and present the User with targeted advertising.

  • Cookie
    google_experiment_mod44
  • Duration
    persistent
  • Description

    Used by Google Ad to experiment with the effectiveness of ads on websites using their services.

Powered by Cookieyes logo

    Get Diamond plan for FREE

    logo

    YS Biopharma Co., Ltd. (YS)

    Price:

    1.02 USD

    ( + 0.09 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    YS
    Name
    YS Biopharma Co., Ltd.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    1.020
    Market Cap
    192.095M
    Enterprise value
    941.054M
    Currency
    USD
    Ceo
    Hui Shao
    Full Time Employees
    773
    Website
    yishengbio.com
    Ipo Date
    2021-08-05
    City
    Beijing
    Address
    Building No. 2

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    BioNTech SE

    VALUE SCORE:

    6

    Symbol
    BNTX
    Market Cap
    22.648B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    ADMA Biologics, Inc.

    VALUE SCORE:

    11

    Symbol
    ADMA
    Market Cap
    3.685B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Harmony Biosciences Holdings, Inc.

    VALUE SCORE:

    12

    Symbol
    HRMY
    Market Cap
    1.610B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -0.588
    P/S
    0.037
    P/B
    0.118
    Debt/Equity
    0.829
    EV/FCF
    -2.946
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    0.665
    Earnings yield
    -1.701
    Debt/assets
    0.303
    FUNDAMENTALS
    Net debt/ebidta
    -7.959
    Interest coverage
    -5.483
    Research And Developement To Revenue
    0.238
    Intangile to total assets
    0.053
    Capex to operating cash flow
    -0.148
    Capex to revenue
    0.029
    Capex to depreciation
    0.487
    Return on tangible assets
    -0.077
    Debt to market cap
    18.290
    Piotroski Score
    2.000
    FUNDAMENTALS
    PEG
    -0.011
    P/CF
    -6.204
    P/FCF
    -9.522
    RoA %
    -7.310
    RoIC %
    -9.154
    Gross Profit Margin %
    82.475
    Quick Ratio
    0.745
    Current Ratio
    1.021
    Net Profit Margin %
    -16.258
    Net-Net
    -3.270
    FUNDAMENTALS PER SHARE
    FCF per share
    -1.299
    Revenue per share
    5.751
    Net income per share
    -0.935
    Operating cash flow per share
    -1.131
    Free cash flow per share
    -1.299
    Cash per share
    0.263
    Book value per share
    4.674
    Tangible book value per share
    3.993
    Shareholders equity per share
    4.674
    Interest debt per share
    4.023
    TECHNICAL
    52 weeks high
    1.780
    52 weeks low
    0.350
    Current trading session High
    1.100
    Current trading session Low
    0.900
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.970

    No data to display

    logo
    Country
    GB
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -3.789

    No data to display

    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -6.290
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.356

    No data to display

    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.250

    No data to display

    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.405

    No data to display

    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.519
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -3.323

    No data to display

    logo
    Country
    GB
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -3.371

    No data to display

    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    14.184
    DESCRIPTION

    YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

    NEWS
    https://images.financialmodelingprep.com/news/ys-biopharma-announces-name-change-to-lakeshore-biopharma-20240524.jpg
    YS Biopharma Announces Name Change to LakeShore Biopharma

    prnewswire.com

    2024-05-24 07:30:00

    GAITHERSBURG, Md. , May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

    https://images.financialmodelingprep.com/news/ys-biopharma-announces-results-of-extraordinary-general-meeting-20240521.jpg
    YS Biopharma Announces Results of Extraordinary General Meeting

    prnewswire.com

    2024-05-21 16:15:00

    GAITHERSBURG, Md. , May 21, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

    https://images.financialmodelingprep.com/news/ys-biopharma-to-hold-extraordinary-general-meeting-on-may-20240507.jpg
    YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer

    prnewswire.com

    2024-05-07 16:20:00

    GAITHERSBURG, Md. , May 7, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

    https://images.financialmodelingprep.com/news/ys-biopharma-receives-additional-180-day-extension-by-nasdaq-20240429.jpg
    YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

    prnewswire.com

    2024-04-29 08:00:00

    GAITHERSBURG, Md. , April 29, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

    https://images.financialmodelingprep.com/news/ys-biopharma-co-ltd-ys-q3-2024-earnings-call-20240419.jpg
    YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript

    seekingalpha.com

    2024-04-19 09:10:18

    YS Biopharma Co., Ltd. (NASDAQ:YS ) Q3 2024 Earnings Conference Call April 19, 2024 8:00 AM ET Company Participants Alyssa Li - Director, Investor Relations David Shao - President & Chief Executive Officer Zenaida Mojares - Chief Medical Officer Brenda Wu - Chief Financial Officer Conference Call Participants Hunter Diamond - Diamond Equity Research Operator Ladies and gentlemen, thank you for standing by and welcome to YS Biopharma's Earnings Call for the First Nine Months of Fiscal Year 2024.

    https://images.financialmodelingprep.com/news/ys-biopharma-announces-unaudited-financial-results-for-the-first-20240419.jpg
    YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

    prnewswire.com

    2024-04-19 07:00:00

    GAITHERSBURG, Md. , April 19, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

    https://images.financialmodelingprep.com/news/ys-biopharma-granted-phase-i-clinical-trial-license-of-20240418.jpg
    YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

    prnewswire.com

    2024-04-18 08:00:00

    GAITHERSBURG, Md. , April 18, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

    https://images.financialmodelingprep.com/news/ys-biopharma-to-report-first-nine-months-of-fiscal-20240416.jpg
    YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

    prnewswire.com

    2024-04-16 08:00:00

    GAITHERSBURG, Md. , April 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

    https://images.financialmodelingprep.com/news/ys-biopharma-announces-positive-interim-results-of-pivotal-phase-20240409.jpg
    YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

    prnewswire.com

    2024-04-09 08:00:00

    GAITHERSBURG, Md. , April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

    https://images.financialmodelingprep.com/news/ys-biopharma-announces-full-repayment-of-us40000000-loan-facility-20240403.jpg
    YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

    prnewswire.com

    2024-04-03 08:00:00

    GAITHERSBURG, Md. , April 3, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

    https://images.financialmodelingprep.com/news/ys-biopharma-announces-board-changes-and-strategic-leadership-appointments-20240305.jpg
    YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries

    prnewswire.com

    2024-03-05 08:00:00

    GAITHERSBURG, Md. , March 5, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

    https://images.financialmodelingprep.com/news/ys-biopharma-announces-results-of-extraordinary-general-meeting-held-on-20240222.jpg
    YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024

    prnewswire.com

    2024-02-22 17:00:00

    GAITHERSBURG, Md. , Feb. 22, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

    https://images.financialmodelingprep.com/news/ys-biopharma-announces-results-of-extraordinary-general-meeting-and-20240216.jpg
    YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting

    prnewswire.com

    2024-02-16 20:20:00

    GAITHERSBURG, Md. , Feb. 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

    https://images.financialmodelingprep.com/news/shareholders-led-by-yi-zhang-announce-successful-results-of-20240216.jpg
    Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.

    prnewswire.com

    2024-02-16 17:36:00

    NEW YORK , Feb. 16, 2024 /PRNewswire/ -- Yi Zhang and shareholders representing over 59.2% of the outstanding shares of YS Biopharma Co., Ltd. (the "Company" or "YS") (NASDAQ: YS) (the "Convening Shareholders") today announced the successful approval of all resolutions at the YS Extraordinary General Meeting of Shareholders ("EGM") held today.

    https://images.financialmodelingprep.com/news/ys-biopharma-to-hold-an-extraordinary-general-meeting-on-20240214.jpg
    YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance

    prnewswire.com

    2024-02-14 08:00:00

    GAITHERSBURG, Md. , Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

    https://images.financialmodelingprep.com/news/ys-biopharma-announces-appointment-of-new-directors-20240214.jpg
    YS Biopharma Announces Appointment of New Directors

    prnewswire.com

    2024-02-14 07:50:00

    GAITHERSBURG, Md. , Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.